

Gastroenterology

Volume 164 / Issue 1

January 2023

www.gastrojournal.org

Contents

ON THE COVER

Gastroenterology



Do Patients With Gastrointestinal Conditions Consider Telehealth Equivalent to In-Person Care? See article by Dobrusin, et al, page 156 for additional information.

COMMENTARIES

- 1 **New Sections in *Gastroenterology*—*Gastro* Curbside Consult and *Gastro* Grand Rounds**
G. Subba Raju, P. Sahni, and S. Wani
- 2 **Reappraisal of Coronavirus Disease 2019 Risk for Patients With Inflammatory Bowel Disease: Withdrawal of the British Society of Gastroenterology Inflammatory Bowel Disease Risk Grid**
R. C. Ungaro and M. D. Kappelman

DIVERSITY, EQUITY, AND INCLUSION IN GI

- 5 **Barriers and Facilitators to Genetic Education, Risk Assessment, and Testing: Considerations on Advancing Equitable Genetics Care**
N. J. Rodriguez, C. Ricker, E. M. Stoffel, and S. Syngal

MENTORING, EDUCATION, AND TRAINING CORNER

- 9 **Structured Medical Education Handles on Twitter: A How-to Guide**
A. Goldowsky, M. Bilal, A. Kickel, and A. Charabaty

EDITORIALS

- 14 **Potassium-Competitive Acid Blocker Suppression of Gastric Acid in Erosive Esophagitis: Is Stronger and Longer Better?**
D. A. Katzka and P. J. Kahrilas
See Laine L et al on page 61.
- 15 **Have We Found the “Holy Grail” That May Predict Response to Immunotherapy in Hepatocellular Carcinoma?**
G. Brandi, F. Tovoli, and S. Tavoroli
See Haber PK et al on page 72.

Video

Related article in CGH

Hot Papers From New Investigators

CME quiz

Editorial accompanies this article

Additional online content available

Cover

Publisher: *Gastroenterology* (ISSN 0016-5085) is published monthly (semi-monthly in April) in two indexed volumes by Elsevier Inc, 230 Park Avenue, New York, NY 10169-0901, USA. Periodicals postage paid at New York, NY and additional mailing offices. POSTMASTER: Send address changes to Elsevier, Journal Returns, 1799 Highway 50 East, Linn, MO 65051, USA. 2023 US subscription rates: individual, \$848.00; student and resident, \$323.00. Outside of the U.S. and possessions: individual, \$1026.00; student and resident, \$596.00; surface delivery, no additional charge; air mail delivery, add \$78.00. Prices subject to change without notice.

- 19 **Fibrosis and Inflammation in Inflammatory Bowel Disease—More Than 2 Sides of the Same Coin?**
L. Welz and K. Aden
See Zhao X et al on page 89.
- 21 **The “Next Generation” of Pancreatic Cyst Fluid Biomarkers?**
K. K. Das
See Paniccia A et al on page 117.

GASTRO CURBSIDE CONSULT

- 24 **An Unusual Presentation of an Appendiceal Adenocarcinoma**
J. Ashcroft, A. Noorani, and C. Simillis
- 27 **Abdominal Pain After Transarterial Chemoembolization**
Z. Salim, A. Laycock, and C. Hewavitharana
- 30 **Abdominal Unidentified Flying Object**
M. E. Presti and M. Lisker-Melman
- 32 **Jaundice and Weight Gain After Autologous Stem Cell Transplantation in a 28-Year-Old Patient With Diffuse Large B-Cell Lymphoma**
K. Mitzlaff, F. Sayk, and P. Solbach

ELECTRONIC GASTRO CURBSIDE CONSULT

For a full list, please see the table of contents online at www.gastrojournal.org.

GASTRO GRAND ROUNDS

- 34 **Picking a Zebra Among Horses: More Difficult Than You Think!**
CME WWW *A. S. Thomas, N. Takahashi, M. J. Levy, S. C. Abraham, C. Fernandez del Castillo, and S. T. Chari*

REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY AND HEPATOLOGY

- 42 **Current Best Practice in Hepatitis B Management and Understanding Long-term Prospects for Cure**
WWW *D. Yardeni, K.-M. Chang, and M. G. Ghany*

ORIGINAL RESEARCH

Full Reports

Esophagus

- 61 **Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial**
E WWW *L. Laine, K. DeVault, P. Katz, S. Mitev, J. Lowe, B. Hunt, and S. Spechler*
See editorial on page 14.

A new type of medication to reduce stomach acid, called vonoprazan, was more effective than a standard type of medication, called lansoprazole, in healing the lining of the esophagus in patients with severe acid reflux disease.

GI Cancer

- 72 **Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma**
E WWW *P. K. Haber, F. Castet, M. Torres-Martin, C. Andreu-Oller, M. Puigvehí, M. Miho, P. Radu, J.-F. Dufour, C. Verslype, C. Zimpel, J. U. Marquardt, P. R. Galle, A. Vogel, M. Bathon, T. Meyer, I. Labgaa, A. Digkila, L. R. Roberts, M. A. Mohamed Ali, B. Mínguez, D. Citterio, V. Mazzaferro, F. Finkelmeier, J. Trojan, B. Özdirik, T. Müller, M. Schmelzle, A. Bejjani, M. W. Sung, M. E. Schwartz, R. S. Finn, S. Thung, A. Villanueva, D. Sia, and J. M. Llovet*
See editorial on page 15.

Here, we define the molecular factors associated with response to frontline anti-PD1 in advanced hepatocellular carcinoma and develop a predictive signature, IFNAP, that can maximize the effectiveness of anti-PD1 in hepatocellular carcinoma.

Intestinal Inflammation

- 89** **Th17 Cell-Derived Amphiregulin Promotes Colitis-Associated Intestinal Fibrosis Through Activation of mTOR and MEK in Intestinal Myofibroblasts**
X. Zhao, W. Yang, T. Yu, Y. Yu, X. Cui, Z. Zhou, H. Yang, Y. Yu, A. J. Bilotta, S. Yao, J. Xu, J. Zhou, G. S. Yochum, W. A. Koltun, A. Portolese, D. Zeng, J. Xie, I. V. Pinchuk, H. Zhang, and Y. Cong
 See editorial on page 19.

Th17 cells induce more severe intestinal fibrosis through the production of AREG, which promotes human intestinal myofibroblast proliferation and migration.

Gut Microbiota

- 103** ***Bacteroides vulgatus* SNUG 40005 Restores *Akkermansia* Depletion by Metabolite Modulation**
H. J. You, J. Si, J. Kim, S. Yoon, K. H. Cha, H. S. Yoon, G. Lee, J. Yu, J.-S. Choi, M. Jung, D. J. Kim, Y. Lee, M. Kim, J. F. Vázquez-Castellanos, J. Sung, J. M. Park, and G. Ko

Bacteroides vulgatus SNUG 40005 reduces body weight and implements metabolites to promote the growth of *Akkermansia* and the integrity of the intestinal barrier in the long-term high-fat diet-induced obese status.

Pancreas

- 117** **Prospective, Multi-Institutional, Real-Time Next-Generation Sequencing of Pancreatic Cyst Fluid Reveals Diverse Genomic Alterations That Improve the Clinical Management of Pancreatic Cysts**
A. Paniccia, P. M. Polanco, B. A. Boone, A. I. Wald, K. McGrath, R. E. Brand, A. Khalid, N. Kubiliun, A. M. O'Broin-Lennon, W. G. Park, J. Klapman, B. Tharian, S. Inamdar, K. Fasanella, J. Nasr, J. Chennat, R. Das, J. DeWitt, J. J. Easler, B. Bick, H. Singh, K. J. Fairley, S. Sarkaria, T. Sawas, W. Skef, A. Slivka, A. Tavakkoli, S. Thakkar, V. Kim, H. D. Vanderveldt, A. Richardson, M. B. Wallace, B. Brahmabhatt, M. Engels, C. Gabbert, M. Dugum, S. El-Dika, Y. Bhat, S. Ramrakhiani, G. Bakis, D. Rolshud, G. Millsbaugh, T. Tielleman, C. Schmidt, J. Mansour, W. Marsh, M. Ongchin, B. Centeno, S. E. Monaco, N. P. Otori, S. Lajara, E. D. Thompson, R. H. Hruban, P. D. Bell, K. Smith, J. B. Permuth, C. Vandenbussche, W. Ernst, M. Grupillo, C. Kaya, M. Hogg, J. He, C. L. Wolfgang, K. K. Lee, H. Zeh, A. Zureikat, M. N. Nikiforova, and A. D. Singhi

See editorial on page 21.

A prospective, multi-institutional, real-time study reveals next-generation sequencing of preoperative pancreatic cyst fluid from >1800 patients improves the classification of pancreatic cysts and detection of early pancreatic cancers.

Hepatobiliary

- 134** **Hepatocyte Adenosine Kinase Promotes Excessive Fat Deposition and Liver Inflammation**
H. Li, J. Zheng, Q. Xu, Y. Yang, J. Zhou, X. Guo, Y. Cai, J. J. Cai, L. Xie, J. Awika, X. Han, Q. Li, L. Kennedy, H. Francis, S. Glaser, Y. Huo, G. Alpini, and C. Wu

Compelling evidence is provided that supports a critical role for hepatocyte adenosine kinase in the pathogenesis of nonalcoholic fatty liver disease by promoting excessive fat deposition and liver inflammation.

RESEARCH LETTERS

- 147** **Inflammatory Bowel Disease Is Associated With Prediagnostic Perturbances in Metabolic Pathways**
X. Hua, R. C. Ungaro, L. M. Petrick, A. T. Chan, C. K. Porter, and H. Khalili, on behalf of the Nurses' Health Study and PREDICTS Collaborators
- 151** **Minimal Risk of Drug-Induced Liver Injury With Molnupiravir and Ritonavir-Boosted Nirmatrelvir**
G. L.-H. Wong, V. W.-K. Hui, T. C.-F. Yip, G. C.-Y. Lui, D. S.-C. Hui, and V. W.-S. Wong
- 154** **Autoimmune Pancreatitis Secondary to Immune Checkpoint Inhibitor Therapy (Type 3 AIP): Insights Into a New Disease From Serial Pancreatic Imaging**
A. S. Thomas, M. Abreo, S. A. Sayed, Y. Wang, S. Yedururi, and S. T. Chari

- 156 **Patients With Gastrointestinal Conditions Consider Telehealth Equivalent to In-Person Care**
 (www) (CD) A. Dobrusin, F. Hawa, J. Montagano, C. X. Walsh, C. Ellimoottil, and N. T. Gunaratnam

CONTINUING MEDICAL EDUCATION (CME)/MOC ACTIVITIES

- e18 **CME Exam 1: Picking a Zebra Among Horses: More Difficult Than You Think!**

GASTRO DIGEST

- 159 **Tirzepatide: A New Anti-Obesity Medication**
S. Ghoneim
- 159 **Endoscopic Sleeve Gastropasty Results in Higher Weight Loss Compared With Lifestyle Modifications Alone**
M. Hanscom
- 160 **Histamine-Producing Bacteria: The Missing Link in Irritable Bowel Syndrome?**
D. Keszthelyi
- 161 **How the Gut Feeds the Brain: A Newly Uncovered Gut-Brain Circuit for Appetite Suppression**
K. G. Margolis

CORRESPONDENCE

- 162 **Active Eradication of *Helicobacter pylori* Within Organized Massive Screening Might Improve Survival of Gastric Cancer Patients**
J.-C. Zou, Y. Yang, and X.-Z. Chen, on behalf of Sichuan Gastric Cancer Early Detection and Screening research group
- 163 **Reply**
L. Yan and W. Ye
- 163 **SERENE CD: Finding Serenity Amid the Clamour**
T. AlAmeel
- 164 **Proactive Therapeutic Drug Monitoring of Adalimumab in Patients With Crohn's Disease**
K. Papamichael, M. C. Dubinsky, and A. S. Cheifetz
- 165 **Statistical Power for Clinical Trials of Proactive Therapeutic Drug Monitoring**
J. D. Lewis
- 166 **Reply**
G. R. D'Haens and W. J. Sandborn

Access to the full content of Gastroenterology Online is available to all subscribers!

AGA members have seamless access to full *Gastroenterology* content from the AGA Web site. Simply sign in to <http://www.gastro.org>, visit the Publications section of the Web site, and click on *Gastroenterology*. You will be directed to the Journal Web site and will have full access to all content without having to supply a different username and password. Members can also visit <http://www.gastrojournal.org> directly and click on "Activate Online Access." Nonmember subscribers must create an online user account and activate their subscription to access the full text of articles on *Gastroenterology* Online. To activate your individual online subscription, please visit <http://www.gastrojournal.org> and click on "Activate Online Access." To activate your account, you

will need your subscriber account or member number, which you can find on your mailing label, (AGA members must use their 10-digit member number, including leading zeros). If you have any questions regarding your online subscription please call Elsevier Customer Service at (800) 654-2452.

Institutional access to *Gastroenterology* Online will be allowed only by limited site licensing. Further instructions will be available online. Personal subscriptions to *Gastroenterology* Online are for individual use only and may not be transferred. Use of *Gastroenterology* Online is subject to agreement to the terms and conditions of use as indicated online.

AGA Member Number

Your Account Number

Sample
mailing
label

GAST0000101864
JANE DOE
531 MAIN ST
CENTER CITY, NY 10001-001

1GAST V91-4 1234567-8
JANE DOE
531 MAIN ST
CENTER CITY, NY 10001-001